
Enovis Corporation
- Jurisdiction
United States - LEI
635400OP2DYYYMOIYL17 - ISIN
US1940145022 (ENOV )- Sectors
Scores
- Fair value (Benjamin Graham formula)
- N/A
- Financial strength (Piotroski F-Value)
-
4
/ 9
- Fundamental strength relative to industry (Mohanram G-Value)
-
2
/ 7
Profile
Enovis Corporation operates as a medical technology company worldwide. Read full profile
Fundamentals
- Net revenue
€1.87B - Gross margin
55.6% - EBIT
-€672.57M - EBIT margin
-36.0% - Net income
-€705.79M - Net margin
-37.8%
Statement period: - (published )
Estimates
Fiscal Year | Net revenue | Net income |
---|---|---|
|
| |
|
| |
N/A | N/A |
Stock price
Dividends
No dividend payouts
Analyst ratings
No analyst ratings available
Insider Transactions
Name | Title | Transaction Date | Shares | Price | Value |
---|---|---|---|---|---|
Tandy Bradley J | SVP and Chief Legal Officer |
|
|
|
|
BERRY PHILLIP BENJAMIN (BEN) | SVP, Chief Financial Officer |
|
|
|
|
PRYOR DANIEL A | EVP, Strategy & Business Dev. |
|
|
|
|
Earnings Calls
Earnings Calls
Latest earnings call: May 2, 2024 (Q1 2024)